期刊
ADVANCES IN THERAPY
卷 27, 期 5, 页码 285-296出版社
SPRINGER
DOI: 10.1007/s12325-010-0038-1
关键词
castration-refractory prostate cancer; docetaxel; cabazitaxel; abiraterone acetate; angiogenesis modulators; vaccines
The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naive or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据